Drugs / TB511
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06400160 | Mar 2026 → Mar 2027 expected | colorectal cancer, hepatocellular carcinoma, non-small cell lung carcinoma, prostate cancer | Twinpig Biolab, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TB511 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06400160 ↗ |
| Action | Deplete | “leading to the destruction of the mitochondria and subsequent death of M2 macrophages.” NCT06400160 ↗ |
| Modality | Peptide | “TB511 is a peptide drug conjugate (PDC)” NCT06400160 ↗ |
| Route | Subcutaneous | “TB511 is a white amorphous powder used for subcutaneous injections.” NCT06400160 ↗ |